Automated Peritoneal Dialysis (APD) market is likely to witness fast-paced growth over the forecast years

Automated Peritoneal Dialysis (APD) is a modality of Peritoneal Dialysis (PD) which is performed by a machine during night time when the patient is asleep. It is also known as Continuous Cyclic Peritoneal Dialysis (CCPD). The system uses the peritoneal membrane of the patient to draw excess and waste fluid from blood.

Download free request sample @ https://goo.gl/p6mDvP

How does it Work?

In this, a machine performs dialysis, the process of removing excess water and other wastes from a patient’s body over a period of 9 to 10 hours. The machine determines the fluids required for each exchange and times its delivery, dwell, and drainage automatically. Approximate training time for this process is around ten days; after that patients can perform this process at home.

New System for Home Dialysis Solution Generation

Growing demand for home dialysis and other home-based treatments has resulted in various technological, as well as product innovations. Thus, a lot of APD system manufacturers are focusing on R&D activities to introduce innovative and easy-to-use systems. For example, Baxter International, Inc. is designing a new system for PD solution generation to produce at-home sterile peritoneal dialysis solutions.

The new system is incorporated with AMIA APD system of the company and is designed to produce sterile PD solutions with the help of a small water filtration device at the patients’ homes. It is also said to decrease the weight and storage handling needs of the traditional PD solutions. According to the company, this system can offer physicians the flexibility to prescribe different dextrose concentrations for every dwell cycle, based on individual requirements.

Visit full report @ https://goo.gl/CmHBx2

Market Overview

Based on the findings of a new research report available on Radiant Insights, Inc.; the global Automated Peritoneal Dialysis (APD) market is likely to witness fast-paced growth over the forecast years (from 2017 to 2022). Growing private investments and venture funding that support novel product innovation are predicted to augment the market in near future.

Moreover, increased government expenditure on healthcare driven by focus on the last-stage renal disease treatments is also anticipated to propel the global market over the next few years. High preference for home-based therapies is also projected to positively affect the market over the forecast period (2017 to 2022).

The global APD market is dominated by various key companies including JMS Co., Ltd.; Baxter International Inc.; Terumo Medical Corp. (TMC); Diaverum Sweden AB; and Fresenius SE & Co. KGaA.